Skip to main content

Table 5 Immunological monitoring in high-grade glioma patients

From: α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

Patient no. DC injection (times) Side effect ELISPOT DTH Th1/Th2 balancea Response
     Peptide DC KLH   
1 1×10 7 (12)   1/5 (MAGE-1)   + + 9.38 PD
2 1×10 7 (24)   4/5 (WT1-1, 1–2, MAGE-1, 3) ++ ++ +++ 0.3 SD
3 1×10 7 (4)   N. D. b     9.67 PD
4 2×10 7 (5) Hepatic (II) 3/5 (WT1-1, 1–2, MAGE-3)     4.09 PD
5 2×10 7 (6)   0   +   6.07 PD
6 2×10 7 (4)   0     2.77 PD
7 5×10 7 (7)   1/5 (gp100)    + 7.08 PD
8 5×10 7 (6)   3/5 (WT1-2, HER2, MAGE-3)     71.4 PD
9 5×10 7 (6)   2/5 (MAGE-1, 3) ++ + + 7.55 PD
  1. a The value shows Th1/Th2 ratio prior to DC vaccination. b N. D. ; not done. PD ; progressive disease, SD ; stable disease.